Skip to main content

Table 1 Patient and treatment characteristics

From: Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation

Characteristic Number Percent
Total 375 100
Median age (yr) 71 (51–92)  
 ≤ 70 yr 185 49.3
 > 70 yr 190 50.7
T stage
 T1-T2 261 69.6
 T3-T4 103 27.5
 Unknown 11 2.9
NCCN risk group
 Intermediate 143 38.1
 High 232 61.9
Gleason Score
 < 8 241 64.3
 8–10 133 35.5
 Unknown 1 0.3
PSA on presentation
 ≤ 20 ng/ml 253 67.5
 > 20 ng/ml 118 31.5
 Unknown 4 1
Median ADT duration (months) 10 (3–36)
Median Radiation Dose (Gy) 72 (70–78)
 < 72 44 11.7
 ≥ 72 327 87.2
 Unknown 4 1.1
  1. NCCN National Comprehensive Cancer Network, ADT androgen deprivation therapy, PSA Prostate-Specific Antigen